Taxol (T) versus doxorubicin (D) as first-line chemotherapy (CT) in advanced breast cancer (ABC): An EORTC randomized study with crossover

1997 ◽  
Vol 33 ◽  
pp. S145 ◽  
Author(s):  
R. Paridaens ◽  
P. Bruning ◽  
J. Klljn ◽  
T. Gamucci ◽  
L. Biganzoli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Randomized Study ◽  
Advanced Breast ◽  
First Line ◽  
Line Chemotherapy

scholarly journals Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer

2002 ◽  
Vol 13 (4) ◽  
pp. 546-552 ◽  
Author(s):  
M. Venturini ◽  
L. Del Mastro ◽  
O. Garrone ◽  
C. Angiolini ◽  
M. Merlano ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Phase I ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Dose Finding ◽  
First Line ◽  
Finding Study ◽  
Dose Finding Study ◽  
Line Chemotherapy

Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study

1985 ◽  
Vol 3 (2) ◽  
pp. 139-148 ◽  
Author(s):  
H. T. Mouridsen ◽  
Michael Cornbleet ◽  
Robin Stuart-Harris ◽  
Ian Smith ◽  
Robert Coleman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
European Study ◽  
First Line ◽  
Line Chemotherapy

Production of P-glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first-line chemotherapy in advanced breast cancer

2007 ◽  
Vol 122 (5) ◽  
pp. 1058-1067 ◽  
Author(s):  
Selina Raguz ◽  
Rebecca A. Randle ◽  
Eva R. Sharpe ◽  
John A. Foekens ◽  
Anieta M. Sieuwerts ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
First Line ◽  
P Glycoprotein ◽  
Upstream Promoter ◽  
Line Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document